But briefly, theres growing evidence that GLP-1 receptor agonists may reduce alcohol consumption, possibly help with other substance use, and potentially address some of the reward dysregulation that underlies both obesity and addiction
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well-established therapeutic agents that exert potent glucose-lowering effects by stimulating insulin secretion, suppressing glucagon secretion in a glucose-dependent manner, and delaying gastric emptying ( Eating behavior is a critical determinant in T2D management ( Although these eating behavior patterns are hypothesized to influence the clinical efficacy of GLP-1RA therapy, direct evidence remains limited
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE maintenance randomized study
Subsequent studies have further illuminated the critical importance of glutamine availability, showing that a reduction in c-MYC protein levels, which leads to diminished cellular proliferation and impaired NK cell function, results primarily from glutamine scarcity rather than the direct inhibition of glutaminolysis [127]
10.1002/jcp.28632 113 LiuJ.ZhangC.LinM.ZhuW.LiangY.HongX.et al (2014)
Without these large-scale studies, we have virtually no reliable information on how BPC-157 affects the human body